Medication info
Egliptin Tablets 25 mg (Sitagliptin Hydrochloride Monohydrate)

Egliptin Tablets 25 mg (Sitagliptin Hydrochloride Monohydrate)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›28.35mg / 1 tablet
Manufacturer / importer
Vivozon Pharmaceutical Co., Ltd.
Appearance
Pink, round, biconvex film-coated tablet
Packaging
PTP - 28 tablets/PTP [(14 tablets/PTP × 2)]
Approval status
Active

MFDS item code 202101298 · Approved 2021.02.16 · Insurance code 658204550

Summary

Main use
Improvement of blood glucose control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
This medicine is administered at a dose of 100 mg once daily as monotherapy or in combination therapy. The maximum daily dose is 100 mg. This medicine may be taken with or without food. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for use, section 5. General precautions). Patients with renal impairment Because dose adjustment based on renal function is necessary, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dose adjustment is necessary in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is necessary in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or patients with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.

Ingredients

Manufacturer
Vivozon Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in type 2 diabetes mellitus

  • Difficulty in controlling blood sugar levels in patients with type 2 diabetes
View approved original text

This medication is used alongside diet and exercise to help control blood sugar levels in patients with type 2 diabetes. Initially, it can be administered as a monotherapy, and if previous treatment with diabetes medications has been inadequate for blood sugar control, it may be used in combination with metformin. Additionally, if monotherapy with sulfonylureas, metformin, thiazolidinediones, or insulin is insufficient, this medication can be administered in conjunction. In cases of more complex combination therapy where blood sugar control is still difficult, this medication can be added to improve efficacy. It aids in effectively managing blood sugar when used alongside various treatment methods.

How to take

Adult dose

This medicine is administered at a dose of 100 mg once daily as monotherapy or in combination therapy. The maximum daily dose is 100 mg. This medicine may be taken with or without food. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for use, section 5. General precautions). Patients with renal impairment Because dose adjustment based on renal function is necessary, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dose adjustment is necessary in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is necessary in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or patients with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.

Precautions

This medication is used for treating diabetes, and some patients may experience serious allergic reactions. These reactions can occur within 3 months of starting the medication, so caution is warranted. During treatment, inflammation of the pancreas (pancreatitis) may develop, so if symptoms such as abdominal pain or vomiting occur, consult a doctor immediately. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis, nor in individuals with allergies to this drug or its components. Patients with impaired kidney function may need to adjust the dosage of this medication, so regular kidney function tests are recommended. In clinical trials, this medication exhibited safety similar to placebo; however, side effects such as pharyngitis, headache, upper respiratory tract infection, and diarrhea were reported. Particularly when taken with insulin or sulfonylureas, the risk of hypoglycemia may increase, so caution is advised. If severe joint pain or skin blisters develop while taking this medication, consult a doctor immediately and discontinue use. Pregnant women are advised not to use this medication, and breastfeeding women should also avoid it. Elderly patients may have reduced kidney function; therefore, dosage adjustments and monitoring of kidney function are necessary. In the event of overdose, standard emergency treatment should be applied, and if needed, some drugs can be removed through hemodialysis. This medication generally has low drug interaction potential when combined with other blood glucose-lowering agents; however, consultation with a doctor is needed when taken with certain medications. This medication has been confirmed to not increase cardiovascular risk in cardiovascular safety trials.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • hypoglycemia
  • nasopharyngitis
  • upper respiratory tract infection
  • headache
  • diarrhea
  • abdominal pain
Show 26 more
  • nausea
  • peripheral edema
  • constipation
  • vomiting
  • severe and disabling arthralgia
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • acute renal failure
  • rash
  • urticaria
  • cutaneous vasculitis
  • dyspepsia
  • dizziness
  • increased serum triglycerides
  • gastritis
  • weight loss
  • hypertension
  • hypernatremia
  • erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is advisable to maintain storage temperatures between 1 degree and 30 degrees Celsius. This storage method helps preserve the drug's efficacy and safety.

Appearance and packaging

Appearance

Pink, round, biconvex film-coated tablet

Package unit

PTP - 28 tablets/PTP [(14 tablets/PTP × 2)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.